(Q46917847)

English

Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland

scientific article published in October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

neovascularization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

author name string

G Donati

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

Journal Francais d'Ophtalmologie

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

30

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

837-841

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

Senile macular degeneration: review of epidemiologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life with macular degeneration: perceptions of patients, clinicians, and community members.

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of recurrence after Verteporfin photodynamic therapy in AMD

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

What is heartburn worth? A cost-utility analysis of management strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2992619-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0181-5512(07)92619-4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

release_rpg4bvhrhzbc7jquakhkndnyea

1 reference

https://api.fatcat.wiki/v0/release/rpg4bvhrhzbc7jquakhkndnyea

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17978682

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46917847&oldid=2137860411"